CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 162 enrolled
Drug / intervention
Sugammadex +1 moredrug
Likely dose
Rocurium 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00474617
NCT00474617Phase 3Completed

A Multicenter, Parallel Group, Comparative, Phase IIIa Trial to Compare the Efficacy, Safety, and Pharmacokinetics of Org 25969 in Elderly Subjects With Adult Subjects

Merck Sharp & Dohme LLC·interventional·Posted May 17, 2007·Updated Apr 2, 2019

In Brief

A Phase 3 clinical trial evaluating Sugammadex and Rocurium for Anesthesia, General. Completed, enrolled 162 participants.

Detailed Summary

The purpose of the study is to compare the effectiveness, safety and pharmacokinetics of sugammadex in participants 65 and over with participants under 65. There is no hypothesis defined for the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 17, 2007
Enrollment StartDec 29, 2005
Primary CompletionOct 20, 2006
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.1 years ago

Interventions

Sugammadexdrug

Rocuriumdrug

intravenous (IV) single bolus dose of 0.6 mg.kg-1